Thomas W. Quinn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas W. Quinn has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Keith L. Ligon
Brigham and Women's Hospital, Boston, MA
1 shared publication Kin-Hoe Chow
Center for Patient-Derived Models, Dana-Farber Cancer Institute, Boston, USA
1 shared publicationLydie L. Debaize
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
1 shared publication- Mark A. Murakami
Harvard Medical School, Boston, Massachusetts
1 shared publication Morvarid Mohseni
Bristol Myers Squibb, Cambridge, USA
1 shared publicationPei-Lun Kao
Center for Patient-Derived Models, Dana-Farber Cancer Institute, Boston, USA
1 shared publication
Latest Publications
- 20 May 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 9 (11) , 1972-1981
High-throughput single-cell density measurements enable dynamic profiling of immune cell and drug response from patient samples
Cell density, the ratio of cell mass to volume, is an indicator of molecular crowding and a fundamental determinant of cell state and function. However, existing density measurements lack the precision or throughput to quantify subtle differences in cell states, particularly in primary samples. Here we present an approach for measuring the density of 30,000 single cells per hour by integrating fluorescence exclusion microscopy with a suspended microchannel resonator. This approach achieves a precision of 0.03% (0.0003 g ml−1) for cells larger than 12 μm in diameter. In human lymphocytes, we discover that cell density and its variation decrease as cells transition from quiescence to a proliferative state, suggesting that the level of molecular crowding decreases and becomes more regulated upon entry into the cell cycle. Using a pancreatic cancer patient-derived xenograft model, we find that the ex vivo density response of primary tumour cells to drug treatment can predict the in vivo tumour growth response. Our method reveals unexpected behaviour in molecular crowding during cell state transitions and suggests density as a biomarker for functional precision medicine.
- 20 May 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 9 (11) , 1972-1981
High-throughput single-cell density measurements enable dynamic profiling of immune cell and drug response from patient samples
Cell density, the ratio of cell mass to volume, is an indicator of molecular crowding and a fundamental determinant of cell state and function. However, existing density measurements lack the precision or throughput to quantify subtle differences in cell states, particularly in primary samples. Here we present an approach for measuring the density of 30,000 single cells per hour by integrating fluorescence exclusion microscopy with a suspended microchannel resonator. This approach achieves a precision of 0.03% (0.0003 g ml−1) for cells larger than 12 μm in diameter. In human lymphocytes, we discover that cell density and its variation decrease as cells transition from quiescence to a proliferative state, suggesting that the level of molecular crowding decreases and becomes more regulated upon entry into the cell cycle. Using a pancreatic cancer patient-derived xenograft model, we find that the ex vivo density response of primary tumour cells to drug treatment can predict the in vivo tumour growth response. Our method reveals unexpected behaviour in molecular crowding during cell state transitions and suggests density as a biomarker for functional precision medicine.